Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells

Published:2015-06-18 Issue:2 Volume:171 Page:205-209
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Evans Andrew G.¹,Rothberg Paul G.¹,Burack W. Richard¹,Huntington Scott F.²,Porter David L.²,Friedberg Jonathan W.³,Liesveld Jane L.³

Affiliation:

1. Department of Pathology and Laboratory Medicine; University of Rochester School of Medicine and Dentistry; Rochester NY USA

2. Department of Medicine and Abramson Cancer Center; University of Pennsylvania Perelman School of Medicine; Philadelphia PA USA

3. Department of Medicine and James P. Wilmot Cancer Institute; University of Rochester School of Medicine and Dentistry; Rochester NY USA

Funder

Alliance for Cancer Gene Therapy (ACGT) Foundation Grant

National Institutes of Health

National Cancer Institute

Novartis Research Grant

James P. Wilmot Cancer Research Fellowship

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13562/fullpdf

Reference15 articles.

1. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias;Brentjens;Blood,2011

2. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia;Brentjens;Science Translational Medicine,2013

3. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma;Davis;Nature,2010

4. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia;Grupp;New England Journal of Medicine,2013

5. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells;Kochenderfer;Blood,2012

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies;Biomedicine & Pharmacotherapy;2024-09

2. CAR-T cell combination therapies in hematologic malignancies;Experimental Hematology & Oncology;2024-07-18

3. Transdifferentiation of diffuse large B-cell lymphoma to a poorly differentiated neoplasm following CAR T-cell therapy;Journal of Hematopathology;2024-06-15

4. Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them;Cancer Drug Resistance;2024-05-14

5. Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies;Seminars in Hematology;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3